PHP.L - Primary Health Properties Plc

LSE - LSE Delayed price. Currency in GBp
150.60
+2.60 (+1.76%)
At close: 4:35PM GMT
Stock chart is not supported by your current browser
Previous close148.00
Open148.80
Bid150.60 x 0
Ask150.80 x 0
Day's range148.02 - 150.80
52-week range107.60 - 151.00
Volume1,296,048
Avg. volume2,586,951
Market cap1.839B
Beta (3Y monthly)0.14
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield0.06 (3.80%)
Ex-dividend date2019-10-10
1y target estN/A
All
News
Press releases
  • EQS Group

    Hardman & Co Research: Primary Health Properties (PHP): High security and accelerating dividend growth

    Hardman & Co Research 05-Aug-2019 / 14:12 GMT/BST * * *Hardman & Co Research: High security and accelerating dividend growth90% of PHP's income is backed by the UK or Republic of Ireland (RoI) governments. Occupancy consistently exceeds 99%. We are confident investors will continue to seek out REITs with strong asset-class focus, particularly categories that provide security of rising income. PHP achieves all this and its dividend per share growth rate is accelerating as a result. In a total contrast to the wider real estate market, rent reviews on PHP assets are accelerating upwards. PHP's growth avenues are expanding. The March 2019 merger with MedicX Fund - as well as a £4m p.a. synergy efficiency and additional investment assets of more than £800m - has added complementary routes to purchase new assets.Please click here for the full report:https://www.hardmanandco.com/research/corporate-research/high-security-and-accelerating-dividend-growth/To contact us:Hardman & Co 35 New Broad Street London EC2M 1NHwww.hardmanandco.comFollow us on Twitter @HardmanandCoContact:Mike Foster +44 20 7194 7633 mf@hardmanandco.com Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case. Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer. * * *Dissemination of a CORPORATE NEWS, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. * * * End of Announcement - EQS News Service

  • EQS Group

    Hardman & Co Research: Primary Health Properties (PHP): Step change, with MedicX Fund merger

    Hardman & Co Research 28-March-2019 / 16:10 GMT/BST * * *Hardman & Co Research: Step change, with MedicX Fund mergerPHP and MedicX Fund completed an all-share recommended merger on 14 March 2019. The latter is also a UK REIT, investing in assets similar to PHP, focused entirely on UK and Republic of Ireland (RoI) primary medical assets. These are localised hubs providing community-based GP surgeries and other closely related medical services. To date, PHP has expanded its presence strongly in this very specialist asset category. The complementary merger adds to capabilities for sourcing investments and enhances cost (fee- and finance-related) synergies, initially by a stated £4.0m p.a. 91% of PHP income is backed by the UK or RoI government. Occupancy consistently exceeds 99%.Please click here for the full report:https://www.hardmanandco.com/research/corporate-research/step-change-with-medicx-fund-merger/To contact us: Hardman & Co 35 New Broad Street London EC2M 1NH www.hardmanandco.com Follow us on Twitter @HardmanandCo Contact: Mike Foster +44 20 7194 7633 mf@hardmanandco.com Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer. * * *Dissemination of a CORPORATE NEWS, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. * * * End of Announcement - EQS News Service

  • PR Newswire

    Investec Asset Management Limited - Form 8.3 - Primary Health Properties Plc

     FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1.         KEY INFORMATION ...

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more